These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18280130)

  • 21. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.
    Milman N; Svendsen CB; Iversen M; Videbaek R; Carlsen J
    Clin Respir J; 2009 Oct; 3(4):207-13. PubMed ID: 20298406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
    Sitbon O; Jaïs X; Savale L; Cottin V; Bergot E; Macari EA; Bouvaist H; Dauphin C; Picard F; Bulifon S; Montani D; Humbert M; Simonneau G
    Eur Respir J; 2014 Jun; 43(6):1691-7. PubMed ID: 24627535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
    Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
    J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
    J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension.
    Halank M; Kolditz M; Opitz C; Hoeffken G; Ewert R
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):54-9. PubMed ID: 16489527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Preliminary study on the efficacy and safety of oral sildenafil in pulmonary arterial hypertension in China].
    Xiong CM; He JG; Lu XL; Shan GL; Wu BX; Zhu XY; Wu GH; Zeng XF; Guo T; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Tian HY; Li WM; Zhang DZ; Zhang C; Li MT; Liu HM; Guo YJ; Shen JY; Zhang WJ; Liu S; Zhou DX; Bao CD; Huang SA; Chen JY; Wu WF; Huang K; Li CL; Wang LH; He B
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):370-4. PubMed ID: 21418907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.
    Ruiz MJ; Escribano P; Delgado JF; Jiménez C; Tello R; Gómez MA; de la Calzada CS
    J Heart Lung Transplant; 2006 Nov; 25(11):1353-7. PubMed ID: 17097500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources.
    Vida VL; Gaitan G; Quezada E; Barnoya J; Castañeda AR
    Cardiol Young; 2007 Feb; 17(1):72-7. PubMed ID: 17184573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination therapy in patients with pulmonary arterial hypertension].
    Ewert R; Opitz CF; Schäper C; Gläser S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
    Kamata Y; Iwamoto M; Minota S
    Lupus; 2007; 16(11):901-3. PubMed ID: 17971364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.
    Gruenig E; Michelakis E; Vachiéry JL; Vizza CD; Meyer FJ; Doelberg M; Bach D; Dingemanse J; Galiè N
    J Clin Pharmacol; 2009 Nov; 49(11):1343-52. PubMed ID: 19755415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.
    Stiebellehner L; Petkov V; Vonbank K; Funk G; Schenk P; Ziesche R; Block LH
    Chest; 2003 Apr; 123(4):1293-5. PubMed ID: 12684325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.
    Barnett CF; Bonura EJ; Nathan SD; Ahmad S; Shlobin OA; Osei K; Zaiman AL; Hassoun PM; Moller DR; Barnett SD; Girgis RE
    Chest; 2009 Jun; 135(6):1455-1461. PubMed ID: 19118270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.